AGMB

AgomAb Therapeutics NV is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for gastrointestinal diseases and fibrotic disorders. Headquartered in Ghent, Belgium, the company specializes in targeting the GPCR receptor family, particularly the leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), which plays a critical role in tissue regeneration and repair. AgomAb's lead product candidate, AGMB-129, is a monoclonal antibody designed to stimulate intestinal stem cell regeneration and is being evaluated for the treatment of gastrointestinal mucositis and inflammatory bowel disease. The company's second program, AGMB-447, targets fibrotic conditions by modulating tissue repair mechanisms. Founded in 2008 as a spin-off from Ghent University and the Flanders Institute for Biotechnology (VIB), AgomAb operates through strategic partnerships and has secured funding from prominent European investors. The company collaborates with academic institutions and industry partners to advance its pipeline through clinical development. In recent years, AgomAb has progressed AGMB-129 through Phase 1b/2a clinical trials, demonstrating its commitment to addressing significant unmet medical needs in regenerative medicine. The company's proprietary platform technology focuses on agonistic antibodies that activate specific GPCRs, representing a differentiated approach in the biotechnology sector. AgomAb continues to expand its research portfolio while advancing its lead candidates toward potential commercialization.